文献速递造血干细胞移植与细胞治疗

移植前EASIX可预测异基因造血干细胞移植后ICU入住

Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation.
PubMed 文献 · Blood Adv · 2021-01-01

本研究在167例连续接受异基因造血干细胞移植的患者中回顾性计算移植前EASIX(EASIX-PRE)并转换为log2值,探索其预测ICU入住的能力并验证其对总生存(OS)和非复发死亡(NRM)的预测价值。结果显示log2-EASIX-PRE可预测ICU入住(HR 1.41,P<.001)、OS(HR 1.19,P=.011)和NRM(HR 1.28,P=.004),且EASIX-PRE>2.795者180天ICU入住率更高(35.8% vs 12.8%,HR 2.28,P=.010)。

要点

  • 移植前EASIX升高与alloHCT后ICU入住风险增加独立相关。
  • EASIX-PRE>2.795者180天ICU入住率35.8%,显著高于低值者的12.8%。
  • EASIX-PRE>1.073者2年OS更低、NRM更高。

核心结论

  • 移植前EASIX可作为识别alloHCT后严重器官功能障碍及ICU入住高风险患者的预后工具。
  • 本研究验证了EASIX-PRE与alloHCT患者OS和NRM的关联。

研究设计与样本

  • 回顾性研究,纳入167例连续接受异基因造血干细胞移植的患者。
  • EASIX-PRE定义为肌酐×乳酸脱氢酶/血小板,并转换为log2值(log2-EASIX-PRE)。

主要发现

  • log2-EASIX-PRE预测ICU入住(HR 1.41;P<.001)、OS(HR 1.19;P=.011)和NRM(HR 1.28;P=.004)。
  • 预测ICU入住的最优EASIX-PRE截断值为第75百分位(2.795),预测OS和NRM的为median值(1.703)。
  • EASIX-PRE>2.795者180天ICU入住率35.8% vs 12.8%(HR 2.28;P=.010)。
  • EASIX-PRE>1.073者2年OS 57.7% vs 68.7%(HR 1.98;P=.006),2年NRM 38.7% vs 18.5%(HR 2.92;P=.001)。
  • log2-EASIX-PRE与移植相关微血管病、肝窦阻塞综合征或急性移植物抗宿主病发生率无关。

关键数值与推荐

  • EASIX-PRE预测ICU入住的最优截断值为2.795(第75百分位)。
  • EASIX-PRE预测OS和NRM的最优截断值为1.703(median值)。

临床怎么用

  • 在移植前评估时计算EASIX-PRE,可辅助识别需要ICU监护的高危患者。
  • 对EASIX-PRE升高的患者可考虑早期个体化干预设计。

局限性

  • 回顾性研究设计。
  • 单中心连续167例样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Endothelial Activation and Stress Index (EASIX) is a laboratory-based prognosis index defined as creatinine × lactate dehydrogenase/platelets. When measured at pretransplantation evaluation (EASIX-PRE), it predicts allogeneic hematopoietic cell transplantation (alloHCT) mortality. This study explores its ability to predict intensive care unit (ICU) admission and validates EASIX-PRE predictive power for overall survival (OS) and nonrelapse mortality (NRM) in 167 consecutive patients undergoing alloHCT. EASIX-PRE was calculated retrospectively in all patients and transformed into log2 values (log2-EASIX-PRE). Log2-EASIX-PRE predicted ICU admission (hazard ratio [HR], 1.41; P < .001), OS (HR, 1.19; P = .011), and NRM (HR, 1.28; P = .004). The most discriminating EASIX-PRE cutoff value for risk of ICU admission was the 75th percentile (2.795); for OS and NRM, it was the median value (1.703). Patients with EASIX-PRE >2.795 had higher incidence of ICU admission in comparison with patients with lower EASIX-PRE values (day +180, 35.8% vs 12.8%; HR, 2.28; P = .010). Additionally, patients with EASIX-PRE >1.073 had lower OS (2 years, 57.7% vs 68.7%; HR, 1.98; P = .006) and higher NRM (2 years, 38.7% vs 18.5%; HR, 2.92; P = .001) than patients with lower EASIX-PRE results. Log2-EASIX-PRE was not associated with incidence of transplantation-associated microangiopathy, sinusoidal obstruction syndrome, or acute graft-versus-host disease. This study proposes EASIX-PRE as a prognostic tool to identify patients undergoing alloHCT at increased risk of severe organ dysfunction and who would therefore require ICU admission. Early identification of patients at high risk of severe events could contribute to personalized intervention design. Additionally, it validates the association between EASIX-PRE and OS and NRM in those undergoing alloHCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Peña M, Salas MQ, Mussetti A, et al. Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation. Blood Adv. 2021. PMID: 34495311. doi:10.1182/bloodadvances.2021004812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。